Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:02 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Aprepitant and Granisetron for the Prophylaxis of Radiation Induced Nausea and Vomiting - A Pilot Study
NCT01183481 · Sunnybrook Health Sciences Centre · PHASE2 · terminated · last registry update 2019-10-09 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study was stopped due to inadequate accrual.” | – | Registry record, Sunnybrook Health Sciences Centre |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TACR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-09-23Results posted on the registry: Vyne Therapeutics Inc., 5 mg Serlopitant Tablets + Matching Placebo Tablets (NCT03841331)
- 2020-09-07Results posted on the registry: Vyne Therapeutics Inc., 5mg Serlopitant Tablets + Placebo Tablets (NCT03546816)
- 2020-09-02Phase 3 first posted: Sun Yat-sen University, olanzapine plus fosaprepitant-based triple regimen + placebo plus fosaprepitant-based triple regimen (NCT04536558)
- 2020-08-07Phase 3 first posted: University of Michigan Rogel Cancer Center, Ondansetron + Dexamethasone (NCT04503668)
- 2020-07-15Results posted on the registry: University of Pennsylvania, Placebo session 1, Aprepitant session 2 + Placebo session 1, Placebo session 2 (NCT01176591)
- 2020-06-18Phase 3 first posted: Fifth Affiliated Hospital, Sun Yat-Sen University, Olanzapine+NK-1 RA+5-HT3 RA + Dexamethasone+NK-1 RA+5-HT3 RA (NCT04437017)
- 2020-04-15Results posted on the registry: Helsinn Healthcare SA, fosnetupitant/ palonosetron + netupitant/palonosetron (NCT03403712)
- 2020-03-31Phase 3 first posted: Vanda Pharmaceuticals, Tradipitant + Placebo (NCT04327661)
- 2020-03-30Phase 3 first posted: Vanda Pharmaceuticals, Tradipitant + Placebo (NCT04326426)
- 2020-01-18Results posted on the registry: University of California, San Diego, Ranolazine + Placebo (NCT01505179)
- 2019-12-17Phase 3 first posted: Consorzio Oncotech, Netupitant/Palonosetron + Dexamethasone (NCT04201769)
- 2019-12-09Also stopped (terminated): Joseph Ma, Netupitant and Palonosetron (NCT03008213)
- 2019-10-28Phase 3 first posted: Vanda Pharmaceuticals, Tradipitant + Placebo (NCT04140695)
- 2019-10-22Results posted on the registry: Vyne Therapeutics Inc., 5 mg Serlopitant Tablets + Matching Placebo Tablets (NCT03282591)
- 2019-09-27Results posted on the registry: Spanish Breast Cancer Research Group, Aprepitant (NCT01298193)
- 2019-09-03Phase 3 first posted: CR-CSSS Champlain-Charles-Le Moyne, Zyprexa® (OLANZapine 5MG) + Emend® (Aprepitant) (NCT04075955)
- 2019-07-22Phase 3 first posted: Vanda Pharmaceuticals, Tradipitant + Placebo (NCT04028492)
- 2019-07-02Results posted on the registry: Jean Yuh Tang, VPD-737 (NCT02654483)
- 2019-06-12Results posted on the registry: Vyne Therapeutics Inc., 5 mg Serlopitant Tablets + Matching Placebo Tablets (NCT03343639)
- 2019-05-22Also stopped (withdrawn): Costantine Albany, Rolapitant + Palonosetron (NCT03960151)
- 2019-05-09Results posted on the registry: Joseph Ma, Netupitant and Palonosetron (NCT03008213)
- 2019-05-08Results posted on the registry: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Aprepitant + Placebo (NCT01149369)
- 2019-03-15Also stopped (terminated): Merck Sharp & Dohme LLC, Fosaprepitant + Placebo for fosaprepitant (NCT02519842)
- 2019-03-15Phase 3 first posted: Mahidol University, aprepitant + olanzapine 10 mg (NCT03876938)
- 2019-03-12Results posted on the registry: Acacia Pharma Ltd, Ondansetron + Placebo (NCT01857232)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision